These findings are strikingly consistent with those of a very recent study examining, among other parameters, ATRX, TP53, and IDH mutational status, along with 1p/19q codeletion in a large cohort of low- and high-grade gliomas [28]. This evidence concerns the gene ATRX and central nervous system cancer.